Search - tctmd.com

Displaying 41 - 60 of 608

Sort: Relevancy | Date

Presentation TCT 2016

Bayesian Statistics: Utility and Interpretation

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Marc Etienne Jolicoeur

November 01, 2016

Presentation TCT 2016

VIDEOTAPED CASE: Percutaneous EVAR Under Conscious Sedation: Demonstration of Technique and Tips

Presenter: D. Christopher Metzger, Peter A. Schneider

November 01, 2016

Presentation TCT 2016

Propensity-Matched Analysis: Advantages and Pitfalls

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Tracy Y. Wang

November 01, 2016

Presentation TCT 2016

Meta-analysis (Standard and Network): The Good, the Bad, and the Ugly

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Somjot S. Brar

November 01, 2016

Presentation TCT 2016

Hypogastric Embolization Is No Longer Necessary in Aorto-iliac EVAR With Contemporary Devices and Techniques

Presenter: D. Christopher Metzger, Peter A. Schneider, Brian G. DeRubertis

November 01, 2016

Presentation TCT 2016

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, David J. Cohen

November 01, 2016

Presentation TCT 2016

Subgroup Analyses: How Useful or Harmful Are They?

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Sanjay Kaul

November 01, 2016

Presentation TCT 2016

Recognition of the Importance of On-Label Use and Appropriate Device Selection in EVAR

Presenter: D. Christopher Metzger, Peter A. Schneider, Barry T. Katzen

November 01, 2016

Presentation TCT 2016

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Usman Baber

November 01, 2016

Presentation TCT 2016

Low-Profile Devices Have Expanded Treatment Options for Patients Undergoing EVAR

Presenter: D. Christopher Metzger, Peter A. Schneider, Ehrin J. Armstrong

November 01, 2016

Presentation TCT 2016

Use of Intravascular Imaging in CTO Intervention

Presenter: Ik-Kyung Jang, Matthew J. Price, Yasushi Asakura

October 31, 2016

Presentation TCT 2016

Uses of Physiology and Imaging During Bifurcation Intervention: What Have We Learned and How Should We Apply This Information?

Presenter: Ik-Kyung Jang, Matthew J. Price, Bon-Kwon Koo

October 31, 2016

Presentation TCT 2016

LM Disease: When to Use FFR, IVUS, or Both

Presenter: Ik-Kyung Jang, Matthew J. Price, Gary S. Mintz

October 31, 2016

Presentation TCT 2016

Improving Clinical Science: Priorities and Methods of Clinical Trials in Cardiovascular Regenerative Medicine

Presenter: Emerson C. Perin, Bernard J. Gersh

October 31, 2016

Presentation TCT 2016

Should the Sequence Be: FFR-PCI-OCT? FFR-PCI-IVUS? Just FFR or just IVUS/OCT? And When Is Angiography Enough?

Presenter: Ik-Kyung Jang, Matthew J. Price, Seung-Jung Park

October 31, 2016

Presentation TCT 2016

Cells at the Moment of Truth: Findings From Meta-analysis and Systematic Reviews

Presenter: Emerson C. Perin, Mariann Gyöngyösi

October 31, 2016

Presentation TCT 2016

Beyond Cells: Cardiac Gene Therapy In Perspective

Presenter: Emerson C. Perin, Marc S. Penn

October 31, 2016

Presentation TCT 2016

Continued Search for the Vulnerable Plaque: Are We Any Closer?

Presenter: Justin E. Davies, Ran Kornowski, Farouc Jaffer

October 31, 2016

Presentation TCT 2016

New Sights from CHART -1 at 1 Year: Relationship of outcomes to baseline biomarkers and treatment intensity

Presenter: Emerson C. Perin, Jozef Bartunek

October 31, 2016

Presentation TCT 2016

Empowering the Angiogram: Angiography-Derived FFR

Presenter: Justin E. Davies, Ran Kornowski

October 31, 2016

Advertisement

Bayesian Statistics: Utility and Interpretation

VIDEOTAPED CASE: Percutaneous EVAR Under Conscious Sedation: Demonstration of Technique and Tips

Propensity-Matched Analysis: Advantages and Pitfalls

Meta-analysis (Standard and Network): The Good, the Bad, and the Ugly

Hypogastric Embolization Is No Longer Necessary in Aorto-iliac EVAR With Contemporary Devices and Techniques

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Subgroup Analyses: How Useful or Harmful Are They?

Recognition of the Importance of On-Label Use and Appropriate Device Selection in EVAR

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Low-Profile Devices Have Expanded Treatment Options for Patients Undergoing EVAR

Use of Intravascular Imaging in CTO Intervention

Uses of Physiology and Imaging During Bifurcation Intervention: What Have We Learned and How Should We Apply This Information?

LM Disease: When to Use FFR, IVUS, or Both

Improving Clinical Science: Priorities and Methods of Clinical Trials in Cardiovascular Regenerative Medicine

Should the Sequence Be: FFR-PCI-OCT? FFR-PCI-IVUS? Just FFR or just IVUS/OCT? And When Is Angiography Enough?

Cells at the Moment of Truth: Findings From Meta-analysis and Systematic Reviews

Beyond Cells: Cardiac Gene Therapy In Perspective

Continued Search for the Vulnerable Plaque: Are We Any Closer?

New Sights from CHART -1 at 1 Year: Relationship of outcomes to baseline biomarkers and treatment intensity

Empowering the Angiogram: Angiography-Derived FFR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content